Amicus Therapies – Leading Biotechnology Company

A global biotechnology company that provides advanced therapy with the ability to treat a wide range of devastating rare diseases is Amicus Therapeutics, Inc. They have a highly intelligent developmental team that is catered to treating human genetic disease. The company is located in Cranbury, New Jersey, where they have been providing treatments since 2007 under the NASDAQ trading symbol FOLD (GoogleFinance). Amicus has a history of being funded by a variety of venture capital firms that include Radius Ventures, Canaan Partners, New Enterprise Associates, and many others. They continually focus their efforts of diseases with particular disorders called lysosomal storage disorders. Amicus Therapeutics divides much of their concentration to focus on Chaperone-Advanced Replacement Therapy that demonstrates a platform of development geared towards enzyme replacement therapies. In 2014, Amicus was known for having the largest portfolio of small molecule pharmacological chaperones in the entire pharmaceutical industry.

 

Amicus Global produced migalastat which is a treatment for Fabry disease that helps to stabilize endogenous mutant alpha-galactosidase. They eventually took part in a three-year collaboration with GlaxoSmithKline and JCR Pharmaceutical to further research the coformulation with recombinant alpha-galactosidase. The combined efforts were performed from 2010 – 2013. Amicus decided to open another site in 2008 which they placed in San Diego.

 

For many years, Amicus Global has been producing lifesaving treatments for those who suffer from genetic disorders. They utilize the most advanced technology with state of the art trained engineers to provide the best products available in the industry. Their platform of technology and products administered with a unique potential rate them to be one of the leading companies in the world (http://alivenewspaper.com/2017/09/amicus-therapeutics-fabry-disease-treatment/). They work hard to continue to provide excellent services for each patient and give them hope for a better future. With their expanding expertise and services throughout the nation, you can expect to hear more from their prosperous work. The employees at Amicus believe in the fight for life and work to support the patient along with their families. They are passionate about what they do and believe in the ethics of the business along with their passion to make a difference.

More about Amicus Therapeutics on MarketWatch

Leave a Reply

Your email address will not be published. Required fields are marked *